信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

III 信息服务

盘后交易 07-15 18:48:43 EDT

3.97

+0.04

+1.02%

盘后3.98

+0.01+0.25%

16:41 EDT

最高4.05	最低3.93	成交量21.00万
今开3.95	昨收3.93	日振幅2.93%
总市值1.90亿	流通市值1.39亿	总股本4,788万
成交额83.68万	换手率0.60%	流通股本3,499万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"III","market":"US","secType":"STK","nameCN":"信息服务","latestPrice":3.97,"timestamp":1784145600000,"preClose":3.93,"halted":0,"volume":210008,"hourTrading":{"tag":"盘后","latestPrice":3.98,"preClose":3.97,"latestTime":"16:41 EDT","volume":2448,"amount":9719.1372384,"timestamp":1784148113684,"change":0.01,"changeRate":0.002519,"amplitude":0.002519},"delay":0,"changeRate":0.010178117048346065,"floatShares":34989300,"shares":47884104,"eps":0.209971,"marketStatus":"盘后交易","change":0.04,"latestTime":"07-15 18:48:43 EDT","open":3.95,"high":4.045,"low":3.93,"amount":836768.8956960001,"amplitude":0.029262,"askPrice":3.98,"askSize":13,"bidPrice":3.58,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.209971,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1784160000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1171256400000,"exchange":"NASDAQ","adjPreClose":3.93,"dividendRate":0.04534,"preHourTrading":{"tag":"盘前","latestPrice":4.0422,"preClose":3.93,"latestTime":"09:24 EDT","volume":377,"amount":1515.900035,"timestamp":1784121857448,"change":0.1122,"changeRate":0.02855,"amplitude":0.015827},"postHourTrading":{"tag":"盘后","latestPrice":3.98,"preClose":3.97,"latestTime":"16:41 EDT","volume":2448,"amount":9719.1372384,"timestamp":1784148113684,"change":0.01,"changeRate":0.002519,"amplitude":0.002519},"volumeRatio":1.115559,"impliedVol":1.5434,"impliedVolPercentile":0.6693},"requestUrl":"/m/hq/s/III","defaultTab":"news","newsList":[{"id":"2651452404","title":"诺诚健华(09969)：soficitinib (ICP-332)治疗中重度特应性皮炎的 III期注册性试验成功达到其主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2651452404","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651452404?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:58","pubTimestamp":1784113097,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华 公布，公司自主研发的新一代口服酪氨酸激酶2抑制剂soficitinib ，用于治疗中重度特应性皮炎患者的III期注册性临床试验成功达到其主要终点。研究结果显示，soficitinib 达到主要终点，在统计学上具有显著性，并取得具有临床意义的改善。公司将继续完成正在进行中的III期研究，包括长期安全性随访，并计划于研究完成后推进soficitinib 用于治疗中重度特应性皮炎的注册申报工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","688428","BK0239","BK1574","BK4134","09969","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651162437","title":"港股异动 | 翰森制药(03692)涨超3% HS-20093治疗小细胞肺癌III期临床研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2651162437","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651162437?lang=zh_cn&edition=full","pubTime":"2026-07-13 09:56","pubTimestamp":1783907799,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，翰森制药涨超3%，截至发稿，涨3.38%，报32.94港元，成交额1.27亿港元。消息面上，7月10日，翰森制药发布公告，集团自主研发的B7-H3靶向抗体–药物偶联物HS20093，在用于经含铂治疗后进展或复发的小细胞肺癌患者关键性III期临床试验中达到总生存期的主要终点。ARTEMIS-008研究详细数据预计未来在国际肿瘤学术会议上予以公布。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1466387.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03692","BK4134","VXUS","III","KCAI","BK1191","BK1589","BK4588","BK4585","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650820851","title":"翰森制药：HS-20093治疗小细胞肺癌III期临床达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2650820851","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650820851?lang=zh_cn&edition=full","pubTime":"2026-07-10 19:37","pubTimestamp":1783683447,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650015739","title":"宜明昂科-B(01541)：IMM0306治疗IgG4相关疾病的II/III期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2650015739","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650015739?lang=zh_cn&edition=full","pubTime":"2026-07-10 12:34","pubTimestamp":1783658046,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B 发布公告，IMM0306 治 疗IgG4 相关疾病 的II/III期试验顺利完成首例患者给药。在严重情况下，该疾病可能导致器官衰竭。现有免疫抑制治疗仍受限于低反应率及高复发率。研究显示，B细胞异常活化及IgG4阳性浆细胞浸润是IgG4-RD的核心病理机制，这与IMM0306的作用机制高度匹配。II/III期临床试验旨在评估IMM0306在降低IgG4-RD患者疾病复发风险方面的疗效，并以此作为其主要终点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465754.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK1161","BK4134","01541","IBBQ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650929828","title":"联合开发心脏药物III期试验未达主要终点，阿斯利康与Ionis股价暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2650929828","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650929828?lang=zh_cn&edition=full","pubTime":"2026-07-09 19:57","pubTimestamp":1783598269,"startTime":"0","endTime":"0","summary":"7月9日，阿斯利康与IONS联合开发的一款实验性心脏病药物在后期临床试验中未能达到主要疗效终点，Ionis股价盘前下跌超20%，阿斯利康盘前跌超8%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/56ac818c9a46212bd08488d4935a4dad","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/56ac818c9a46212bd08488d4935a4dad"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465485.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1267930573.SGD","LU0320765992.SGD","BK4134","LU2468319806.SGD","LU0109394709.USD","LU2089984988.USD","BK4568","LU0029864427.USD","AZN","LU0708994859.HKD","LU2237443465.HKD","LU2237443622.USD","BK4007","LU2462157665.USD","IONS","BK4588","LU2417539215.USD","LU0310800379.SGD","LU2237443978.SGD","III","LU2236285917.USD","LU2237443895.HKD","LU0058720904.USD","LU2237443382.USD","LU0128525929.USD","BK4139","LU1829250122.USD","AZNH","LU2456880835.USD","LU0432979614.USD","LU2237443549.SGD","LU0289739699.SGD","LU0889565916.HKD","BK4585","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2650929827","title":"联合开发心脏药物III期试验未达主要终点 阿斯利康(AZN.US)与Ionis(IONS.US)股价暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2650929827","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650929827?lang=zh_cn&edition=full","pubTime":"2026-07-09 19:29","pubTimestamp":1783596558,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1829250122.USD","LU0889565916.HKD","BK4588","LU2462157665.USD","LU2237443465.HKD","LU2417539215.USD","LU2237443895.HKD","III","IE00B3T34201.USD","LU0289739699.SGD","LU0029864427.USD","LU0708994859.HKD","AZNH","BK4134","BK4585","LU0310800379.SGD","LU2456880835.USD","LU2236285917.USD","LU0320765992.SGD","LU2237443978.SGD","LU2237443622.USD","LU0432979614.USD","LU2089984988.USD","LU2468319806.SGD","BK4007","LU2237443382.USD","LU2237443549.SGD","AZN","BK4568","LU1267930573.SGD","LU0058720904.USD","BK4139","LU0109394709.USD","LU0128525929.USD","IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650947562","title":"海西新药(02637)：C019199片启动骨肉瘤III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2650947562","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650947562?lang=zh_cn&edition=full","pubTime":"2026-07-09 16:39","pubTimestamp":1783586357,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海西新药 发布公告，公司自主研发的C019199片正式启动针对既往至少二线治疗失败的骨肉瘤的III期临床试验，相关信息已获中国国家药品监督管理局药品审评中心药物临床试验登记与资讯公示平台公示。C019199片是海西新药基于自主构建的MultiSel-Opt小分子创新药物研发平台开发的全球首创多靶点肿瘤免疫调节剂。C019199片的III期临床启动，标志着集团在晚期骨肉瘤治疗领域的创新管线迈出了关键一步，有望为患者提供全新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465274.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","BMED","III","BK1191","IBBQ","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649561956","title":"英硅智能(03696)：Rentosertib启动III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2649561956","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649561956?lang=zh_cn&edition=full","pubTime":"2026-07-08 08:42","pubTimestamp":1783471368,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英硅智能 发布公告，英硅智能自主研发的Rentosertib 正式启动III期临床试验，相关信息已获中国国家药品监督管理局药品审评中心官方注册平台公示，并于 ClinicalTrials.gov网站登记。该项前瞻性、随机、双盲、安慰剂对照、平行组III期研究计划评估Rentosertib每日一次、连续用药52周的有效性及安全性，预计于全国47个研究中心招募共320 名受试者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464475.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK4134","IBBQ","BMED","03696","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649587956","title":"英硅智能首款AI药物进入III期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2649587956","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649587956?lang=zh_cn&edition=full","pubTime":"2026-07-08 08:39","pubTimestamp":1783471140,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CHAT","QTOC","III","VTHR","AGIX","BK4134","ARTY","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649672669","title":"多家大型银行已就收购富达国民信息服务的一个支付网络展开初步磋商，该网络可帮助银行绕过联邦借记卡费率上限规定。","url":"https://stock-news.laohu8.com/highlight/detail?id=2649672669","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649672669?lang=zh_cn&edition=full","pubTime":"2026-07-07 07:02","pubTimestamp":1783378965,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647573265","title":"Vistagen公布社交焦虑症药物III期试验顶线及事后分析数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2647573265","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647573265?lang=zh_cn&edition=full","pubTime":"2026-06-30 22:43","pubTimestamp":1782830580,"startTime":"0","endTime":"0","summary":"Vistagen近日公布了其fasedienol鼻喷雾剂用于社交焦虑症急性治疗的PALISADE-4 III期公共演讲挑战试验的顶线结果及事后分析数据。该试验是Vistagen注册导向的PALISADE III期项目的重要组成部分。不过，fasedienol在PALISADE-3中的安全性数据与此前试验一致，未报告药物相关的严重不良事件。　　Vistagen强调，PALISADE-2此前已取得积极结果。　　社交焦虑症在美国影响超过3000万成年人，目前尚无FDA批准的急性治疗药物。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-30/doc-iniffcpn1443632.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647555422","title":"石药集团(01093.HK)：SYS 6010联合恩朗苏拜单抗用于辅助治疗已切除的II -IIIB期驱动基因阴性、未达到MPR非小细胞肺癌的III期临床研究在中国正式启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2647555422","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647555422?lang=zh_cn&edition=full","pubTime":"2026-06-30 22:10","pubTimestamp":1782828601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4134","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647589491","title":"港股异动 | 天辰生物-B(01779)涨超6% LP-003针对季节性过敏性鼻炎适应症III期临床试验达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2647589491","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647589491?lang=zh_cn&edition=full","pubTime":"2026-06-30 11:02","pubTimestamp":1782788555,"startTime":"0","endTime":"0","summary":"消息面上，近日，天辰生物-B发布公告，LP-003针对季节性过敏性鼻炎的III期临床试验已达到预先设定的主要终点，且该等结果在统计学及临床方面均具有高度重要性。LP-003针对季节性过敏性鼻炎适应症的III期临床试验是一项在中国开展的多中心、随机、双盲、安慰剂对照的III期临床研究，旨在比较LP-003与安慰剂治疗经标准治疗控制不佳的中重度季节性过敏性鼻炎的效果。此外，LP-003 II期临床数据初步展现出超越奥马珠单抗的潜力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460968.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK1161","01779","BK4585","BK4588","BK4134","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646086842","title":"信达生物合作伙伴Ollin Biosciences宣布完成超额认购的3.3亿美元B轮融资，以推进IBI324（OLN324）在DME和wAMD中的全球III期临床开发；研究计划于2026年下半年启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2646086842","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646086842?lang=zh_cn&edition=full","pubTime":"2026-06-25 08:00","pubTimestamp":1782345600,"startTime":"0","endTime":"0","summary":"Ollin Biosciences B轮融资所得将用于支持OLN324在糖尿病性黄斑水肿或湿性年龄相关性黄斑变性 的全球III期临床开发，及推进其他创新分子于今年进入临床开发阶段。Ollin计划于2026年下半年启动OLN324治疗DME和wAMD的全球III期临床试验，并将与信达生物合作在中国、韩国等招募患者。截至目前，信达生物患者援助项目已惠及20余万普通患者，药物捐赠总价值40亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4991487_ZH91487_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0455707207.USD","BK1589","LU2097828474.EUR","LU2097828714.EUR","LU0502904849.HKD","BK4134","LU2097828805.USD","01801","LU1969619763.USD","LU2097828631.EUR","BK1161","LU2488822045.USD","III","LU2328871848.SGD","LU2242644610.SGD","HK0000165453.HKD","BK1583","LU2097828557.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645697863","title":"新股首日 | 麦科医药-B(02335)首挂上市 早盘高开86.92% 核心产品MT1013正处于III期临床阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2645697863","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645697863?lang=zh_cn&edition=full","pubTime":"2026-06-24 09:25","pubTimestamp":1782264328,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，麦科医药-B首挂上市，公告显示，每股定价18.2港元，共发行5805.44万股股份，每手200股，所得款项净额约10.67亿港元。截至发稿，涨86.92%，报34.02港元，成交额2.17亿港元。公开资料显示，麦科医药已自主开发由一项核心产品及其他六项候选产品组成的产品管线。预计公司的MT1013将于2028年初商业化，公司将实行双轨商业化策略：在国内透过与第三方合约销售组织合作，在国际上则透过授权合作伙伴关系。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457891.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","IPOS","BK4134","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645097981","title":"轩竹生物-B(02575)：安奈拉唑钠新适应症根除幽门螺杆菌之III期临床试验完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2645097981","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645097981?lang=zh_cn&edition=full","pubTime":"2026-06-21 18:11","pubTimestamp":1782036715,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B 发布公告，团自主研发的创新药安奈拉唑钠肠溶片用于含安奈拉唑钠的铋剂四联疗法根除幽门螺杆菌之III期临床研究，近日已成功完成首例患者入组，标志着该项关键注册临床研究正式迈入实质性执行阶段。本次Hp根除适应症III期临床研究于2026年4月获中国国家药品监督管理局药品审评中心批准开展后，迅速完成首例患者入组，充分彰显公司临床开发团队的高效执行能力，亦标志该项目正式进入临床执行关键阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456624.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","02575","BK4134","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644777227","title":"【券商聚焦】西南证券：英硅智能(03696)核心管线III期临床启动 若成功上市有望成颠覆性疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2644777227","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644777227?lang=zh_cn&edition=full","pubTime":"2026-06-18 14:22","pubTimestamp":1781763776,"startTime":"0","endTime":"0","summary":"金吾财讯 | 西南证券发布研报指，英硅智能 于2026年6月13日召开核心管线Rentosertib用于治疗特发性肺纤维化的III期临床试验研究者会议。Rentosertib是全球首款完全由生成式AI发现并完成IIa期临床的候选药物。若成功上市，有望成为颠覆性疗法。主要风险包括创新药研发和商业化不及预期、竞争加剧、行业政策变化。","market":"other","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984105","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","600369","BK0012","BK0188","BK4134","BK0028","III","BK0183","BK0276","03696","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642264255","title":"40亿美元买来的AI药物，III期头对头打败BMS，预计明年上市！","url":"https://stock-news.laohu8.com/highlight/detail?id=2642264255","media":"智药局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642264255?lang=zh_cn&edition=full","pubTime":"2026-06-12 18:03","pubTimestamp":1781258580,"startTime":"0","endTime":"0","summary":"一款AI药物，III期实验成功！昨晚，武田公布了这款TYK2药物的最新III期临床信息。数据显示，该药物头对头疗效直接完胜BMS同靶点药物Sotyktu！武田计划在2027年上半年，将zasocitinib正式推向市场。由此，Sotyktu成为全球首款获批上市的TYK2抑制剂。目前该药物已经以1亿元首付款成功对外授权。这是中国率先由AI辅助设计、进入III期确证性临床的小分子药物。III期试验计划在中国招募约750名超重或肥胖受试者，进行52周评估，预计2028年底或2029年上市。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-06-12/doc-iniccwvp3522336.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CHAT","IPOS","III","AIPO","BK4134","AGIX","BMS","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642237531","title":"天辰生物-B(01779)：LP-003针对季节性过敏性鼻炎适应症的III期临床试验达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2642237531","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642237531?lang=zh_cn&edition=full","pubTime":"2026-06-12 06:16","pubTimestamp":1781216203,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天辰生物-B 发布公告，LP-003针对季节性过敏性鼻炎的III期临床试验已达到预先设定的主要终点，且该等结果在统计学及临床方面均具有高度重要性。LP-003针对季节性过敏性鼻炎适应症的III期临床试验是一项在中国开展的多中心、随机、双盲、安慰剂对照的III期临床研究，旨在比较LP-003与安慰剂治疗经标准治疗控制不佳的中重度季节性过敏性鼻炎的效果。主要排除标准为患有季节性过敏性鼻炎以外的合并症的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453442.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","01779","III"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2642842817","title":"康宁杰瑞制药-B(09966)：安尼妥单抗(KN026)一线治疗HER2阳性晚期乳腺癌的III期临床研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2642842817","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642842817?lang=zh_cn&edition=full","pubTime":"2026-06-10 19:05","pubTimestamp":1781089518,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B 发布公告，与石药集团有限公司附属公司上海津曼特生物科技有限公司合作开发的安尼妥单抗联合注射用多西他赛用于人类表皮生长因子受体2阳性晚期乳腺癌一线治疗的III期临床研究，经独立数据监察委员会评估，成功达到预先设定的主要终点无进展生存期，结果具有显著的统计学和临床双重意义。曲妥珠单抗联合帕妥珠单抗和多西他赛目前仍是国内外HER2+晚期乳腺癌一线治疗的首选方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452724.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","III","BK1574","09966","BK4134"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.isg-one.com","stockEarnings":[{"period":"1week","weight":-0.032},{"period":"1month","weight":-0.0665},{"period":"3month","weight":-0.0415},{"period":"6month","weight":-0.3536},{"period":"1year","weight":-0.1914},{"period":"ytd","weight":-0.3201}],"compareEarnings":[{"period":"1week","weight":0.0055},{"period":"1month","weight":0.0136},{"period":"3month","weight":0.0741},{"period":"6month","weight":0.0861},{"period":"1year","weight":0.2033},{"period":"ytd","weight":0.1025}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Information Services Group, Inc.于2006年7月20日在特拉华州注册成立。该公司是一家全球领先的技术研究和咨询公司。ISG是超过900家客户、超过75家百强企业值得信赖的商业伙伴，致力于帮助企业、公共部门组织以及服务和技术提供商实现卓越运营和更快增长。该公司专门从事数字化转型服务，包括自动化、云和数据分析；采购咨询；托管治理和风险服务；网络载体服务；技术战略和运营设计；变革管理；市场情报和技术研究与分析。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.022101},{"month":2,"riseRate":0.5,"avgChangeRate":0.004642},{"month":3,"riseRate":0.315789,"avgChangeRate":0.030463},{"month":4,"riseRate":0.473684,"avgChangeRate":-0.00444},{"month":5,"riseRate":0.368421,"avgChangeRate":-0.021525},{"month":6,"riseRate":0.473684,"avgChangeRate":0.009959},{"month":7,"riseRate":0.421053,"avgChangeRate":0.011214},{"month":8,"riseRate":0.555556,"avgChangeRate":0.010481},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.004212},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.036611},{"month":11,"riseRate":0.611111,"avgChangeRate":0.053419},{"month":12,"riseRate":0.555556,"avgChangeRate":0.003262}],"exchange":"NASDAQ","name":"信息服务","nameEN":"Information"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信息服务,III,信息服务股票,信息服务股票老虎,信息服务股票老虎国际,信息服务行情,信息服务股票行情,信息服务股价,信息服务股市,信息服务股票价格,信息服务股票交易,信息服务股票购买,信息服务股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}